Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
Pembrolizumab (Keytruda) plus chemo did not significantly improve event-free survival (EFS) in cisplatin-eligible muscle-invasive bladder cancer (MIBC) patients, per KEYNOTE-866 trial results. Median EFS was 74.1 months with pembrolizumab vs not reached with placebo (HR 0.88, P = .1366). Overall survival (OS) was similar, and pCR rate was higher with pembrolizumab. Adverse effects were consistent with prior reports. The trial enrolled 907 patients, with EFS as the primary endpoint.
How this was made
The 30-second read
Why it matters
The miss of the primary endpoint is a material clinical‑trial disclosure for Merck, likely influencing its stock price immediately.
Market read
First disclosure of pivotal trial results for a major oncology drug; high relevance for Merck and the broader immuno‑oncology sector.
What to watch
The trial still showed a numerically higher pCR and comparable safety, which could support future combination strategies.
Background
The article reports first‑time presentation of the KEYNOTE‑866 phase‑3 data at the 2026 ESMO Congress.
Ticker impact
Merck's Phase 3 KEYNOTE-866 trial of pembrolizumab plus chemo failed to meet the primary EFS endpoint in cisplatin‑eligible muscle‑invasive bladder cancer.
likely pressure as the market prices in the missed efficacy result
Phase‑3 data are material; the miss of a primary endpoint for a major oncology asset typically depresses the stock on the day of release.
Market effects
May dampen enthusiasm for immunotherapy combinations in bladder cancer and could affect peer oncology stocks.
US biotech sector could see modest downside pressure.
Global oncology pipeline investors may reassess similar pembrolizumab‑based regimens.
Counterpoint
Some investors may view the modest OS similarity and higher pCR rate as a longer‑term upside catalyst.
Key entities
- CompanyMerck & Co., Inc.
Pharmaceutical company developing pembrolizumab (Keytruda).
- Clinical TrialKEYNOTE-866
Phase‑3 study evaluating perioperative pembrolizumab plus chemotherapy in MIBC.
